SEC Form 4 · accession 0000899243-17-002871
NEKTAR THERAPEUTICS · NKTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Nicholson
Officer — SVP & Chief Operating Officer
Period of report
Feb 2, 2017
Accepted (ET)
Feb 6, 2017 · 5:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000906709
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 2, 2017 | M | 66,495 | $4.65 | A | 206,821 | D | |
| Common StockF1,F2 | Feb 2, 2017 | S | 66,495 | $12.38 | D | 140,326 | D | |
| Common StockF1 | Feb 3, 2017 | M | 8,505 | $4.65 | A | 148,831 | D | |
| Common StockF1,F3 | Feb 3, 2017 | S | 8,505 | $12.48 | D | 140,326 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F4 | $4.65 | Feb 2, 2017 | M | 66,495 | D | — | Feb 22, 2017 | Common Stock | 66,495 | 53,505 | D |
| Employee Stock Option (right to buy)F4 | $4.65 | Feb 3, 2017 | M | 8,505 | D | — | Feb 22, 2017 | Common Stock | 8,505 | 45,000 | D |
Explanation of responses
- F1The Reporting Person exercised and sold a portion of the Shares of common stock subject to this stock option that expires on February 22, 2017, with the objective of using substantially all of the proceeds to cover the exercise price of the entire stock option and applicable withholding taxes.
- F2This price reflects the weighted average sale price for open-market sales of Shares made by the Reporting Person on February 2, 2017. The actual prices for these transactions range from $12.20 to $12.45, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- F3This price reflects the weighted average sale price for open-market sales of Shares made by the Reporting Person on February 3, 2017. The actual prices for these transactions range from $12.45 to $12.51, inclusive.
- F4This stock option became fully vested on February 23, 2013 and will expire on February 22, 2017 if not exercised.